EMBLA MEDICAL®

Q2 ▪ 2026

Interim Report Q2 2026 *Announcement no. 38/2026*

Sveinn Sölvason, President and CEO, comments:

"Sales in Q2 2026 were USD 259 million, representing 11% reported growth and 6% organic growth. Strong double-digit Prosthetics & Neuro Orthotics growth in Q2, supported by excellent execution, robust volume growth in EMEA and APAC, and successful new product launches. Bracing & Supports delivered moderate growth in the quarter, while Patient Care declined.

In Patient Care, we continue to see encouraging progress, with most of our clinics delivering increased productivity and profitability. However, Q2 sales remained below expectations due to timing effects and challenging market dynamics in selected key European markets. As these factors continue to normalize, management remains confident that performance will improve over the coming periods and gradually return to growth broadly in line with the structural growth of the O&P industry.

The EBITDA margin was strong at 22% in Q2 2026, up 1%-point from Q2 2025, reflecting solid sales contribution from Prosthetics & Neuro Orthotics, continued cost discipline, and US tariff refunds.

Based on our first half performance and expectations for stronger growth in H2 2026, we are narrowing our full-year organic sales growth guidance to 5-7% (previously 5-8%). We reiterate our EBITDA margin guidance of 20-22%."

Highlights Q2 2026

- Sales amounted to USD 259m, growing 11% reported, 6% organically and 9% in local currencies incl. M&A.
- Organic sales growth by segment: Prosthetics & Neuro Orthotics +12%, Bracing & Supports +1%, Patient Care -2%.
- Gross profit margin was 63%, compared to 62% in Q2 2025. The gross profit margin in the quarter was positively impacted by strong sales in Prosthetics & Neuro Orthotics and net US tariff refunds USD 3 million.
- EBITDA amounted to USD 58 million, corresponding to a margin of 22% of sales, up from 21% in Q2 2025. The margin increase was driven by a higher gross profit margin and continued SG&A cost discipline.
- Net profit was USD 29 million and increased by 39% compared to Q2 2025 with a net profit margin of 11%. The increase was driven by growing operating results and lower net financial expenses than in the comparable quarter.
- Free cash flow amounted to USD 31 million or 12% of sales, compared to 5% of sales in Q2 2025. Free cash flow was solid in the quarter, benefitted from strong operating results, lower net working capital investments than in the comparable quarter and moderate CAPEX.
- NIBD/EBITDA before special items was 2.2x at the end of Q2 2026, which is within our target range of 2-3x EBITDA. During Q2 2026, Embla Medical bought back 1,323,653 shares at a market value of USD 5.5 million. The existing Share Buyback Program concluded on 17 July 2026. A new share buyback program of up to 2 million shares initiated on 20 July 2026.

Other highlights

- At the OTWorld Congress in Leipzig in May, Embla Medical's full brand portfolio was on display, with Össur, College Park, Fior & Gentz, Streifeneder and ForMotion all represented at the industry's largest global trade fair. The event attracted more than 21,000 visitors from 92 countries, generating strong engagement with healthcare professionals and industry decision makers.
- All patient care facilities included in the rollout program have now transitioned to the ForMotion brand, marking an important milestone in our patient care transformation uniting our global clinic network under a single, patient-centered brand.
- Six new innovations launched during Q2 2026 across Prosthetics, Neuro orthotics and Bracing & Supports (detailed overview on page 9).
- Progress according to plan in developing our first dedicated microprocessor knee for less-mobile users (K2). A fully integrated system prototype has been successfully assembled for upcoming verification and validation activities. On track towards launch in late 2027.

2026 Outlook

- Organic sales growth guidance narrowed to 5-7% (previously 5-8%).
- EBITDA margin before special items guidance is unchanged at 20-22%.

	H1 2026	H1 2025	Q2 2026	Q2 2025	Guidance (current)	Guidance (previously)
Sales growth, organic	5%	4%	6%	5%	5-7%	5-8%
EBITDA margin, before special items	20%	20%	22%	21%	20-22%*	20-22%*

*Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical's financial results, but some absorption of tariffs is assumed in the guidance.

USD millions		Q2 2026	Q2 2025	1H 2026	1H 2025	FY 2025	FY 2024	FY 2023	FY 2022
Income Statement									
Net sales		259	232	491	435	929	855	786	719
Gross profit		164	144	307	272	579	535	486	440
Operating expenses (excl. other income / exp.)		122	111	243	217	454	422	398	373
EBITDA		58	49	98	85	186	169	139	114
EBITDA before special items		58	49	98	85	186	173	139	128
EBIT		42	34	66	56	125	113	89	65
Net profit		29	21	44	33	84	69	59	43
Sales Growth									
Sales growth USD	%	11	7	13	4	9	9	9	0
Growth breakdown:									
Organic growth	%	6	5	5	4	6	6	9	4
Currency effect	%	2	2	5	0	2	0	(1)	(7)
Acquired business	%	3	0	3	0	1	3	1	3
Balance Sheet									
Total assets		1,717	1,677	1,717	1,677	1,730	1,539	1,386	1,325
Equity		926	836	926	836	896	781	705	636
Net interest-bearing debt (NIBD)		435	472	435	472	439	414	395	404
Cash Flow									
Cash generated by operations		52	34	72	57	178	160	126	92
Free cash flow		31	12	35	20	100	77	52	35
Key Ratios									
Gross profit margin	%	63	62	63	63	62	63	62	61
EBIT margin	%	16	15	13	13	13	13	11	9
EBITDA margin	%	22	21	20	20	20	20	18	16
EBITDA margin before special items	%	22	21	20	20	20	20	18	18
Equity ratio	%	54	50	54	50	52	51	51	48
Net debt to EBITDA before special items*		2.2	2.6	2.2	2.6	2.4	2.4	2.8	3.2
Effective tax rate	%	23	24	23	24	23	24	23	23
Return on equity*	%	11	9	11	9	10	9	9	7
CAPEX / Net sales	%	2.3	4.4	2.3	3.8	3.4	4.6	5.4	3.6
Market									
Market value of equity		1,749	2,250	1,749	2,250	2,202	2,125	1,713	2,035
Number of shares in millions		428	428	428	428	430	428	421	423
Basic EPS in US cents		6.9	5.0	10.2	7.8	19.6	16.2	14.0	10.3
Diluted EPS in US cents		6.8	5.0	10.2	7.8	19.6	16.2	14.0	10.3

* Financial ratios are based on operations for the preceding 12 months.

EMBLA MEDICAL®

Management's report

Financial performance

Sales

Sales increased by 6% organic in Q2 2026

Sales in 1H 2026 amounted to USD 491 million, compared to USD 435 million in 1H 2025, corresponding to 5% organic growth, 8% local currency growth (including 3%-points from M&A) and 13% reported growth (USD growth). Sales in Q2 2026 amounted to USD 259 million, compared to USD 232 million in Q2 2025, corresponding to 6% organic growth, 9% local currency growth (including 3%-points from M&A) and 11% reported growth (USD growth).

Positive FX impact of USD 6 million in Q2 2026

Reported sales were USD 6 million higher in Q2 2026 due to changes in FX when compared to Q2 2025, which corresponds to about a 2%-point positive effect on the reported growth rate.

Sales by geographical segment (USD million)	Q2 2026	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth	1H 2026	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth
EMEA	134	8%	6%	4%	18%	258	6%	6%	8%	20%
Americas	105	3%	0%	0%	3%	193	3%	0%	1%	3%
APAC	20	9%	0%	6%	15%	40	11%	0%	7%	18%
Total	**259**	**6%**	**3%**	**2%**	**11%**	**491**	**5%**	**3%**	**5%**	**13%**

Sales by business segment (USD million)	Q2 2026	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth	1H 2026	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth
Prosthetics & Neuro Orthotics	151	12%	6%	2%	20%	287	10%	6%	5%	21%
Bracing & Supports	39	1%	0%	2%	3%	76	1%	0%	3%	4%
Internal product sales	(11)	10%	1%	3%	13%	(21)	7%	1%	5%	13%
External sales	**179**	**10%**	**5%**	**2%**	**16%**	**342**	**8%**	**5%**	**4%**	**17%**
Patient Care	79	-2%	0%	3%	1%	149	-2%	0%	5%	4%
Total	**259**	**6%**	**3%**	**2%**	**11%**	**491**	**5%**	**3%**	**5%**	**13%**

Strong growth in EMEA and APAC in Q2 2026

Growth in Q2 2026 was driven by strong volume growth in Prosthetics & Neuro Orthotics.

Sales growth in EMEA remained strong in Q2, with 8% organic growth driven by robust Prosthetics performance across both key European markets and newer markets, including Ukraine. Growth was supported by strong volumes and broad-based demand across key product categories, including Bionics. Recently acquired Streifeneder also made a solid contribution. Neuro Orthotics delivered another quarter of strong growth, with broad-based momentum across the region. Bracing & Supports sales ended down, driven by tough competition and shifting market dynamics. Patient Care sales declined, mainly due to timing effects and challenging market dynamics in selected key European markets such as France and Sweden. As these factors normalize, management expects sales performance to improve over the coming periods and gradually return to growth broadly in line with the structural growth of the O&P industry.

In the Americas, organic sales growth was 3% in the second quarter. Prosthetics growth in the US has begun to pick up, supported by solid performance in core portfolio and continued momentum in Bionics, with strong contributions from Navii, Proprio, Icon, and Odyssey iQ. Neuro Orthotics continued to build momentum in the US, delivering strong growth from a low base, with a more meaningful contribution expected in the coming periods as the rollout of our first bionic knee joint expands. Bracing & Supports generated solid growth, driven by higher volumes and broad-based demand across core products. Patient Care sales growth was strong across key markets with performance trending in the right direction.

In APAC, organic sales growth was strong at 9% in the second quarter. Prosthetics & Neuro Orthotics growth was led by Australia, with broad-based strength across most product categories, supported by solid growth across the rest of Asia. Bracing & Supports delivered solid growth in Australia and New Zealand, driven by increased demand for premium solutions. Patient Care continued to perform well in Australia.

As previously communicated, Patient Care underperformed through most of 2025, mainly in EMEA and the Americas, due to lower patient volumes and implementation of strategic initiatives in Patient Care, including the ForMotion rebranding, system integrations, and other operational changes that temporarily affected performance. In the second half of 2025, we launched several strategic initiatives to strengthen performance management and support sustainable growth and improved profitability. These actions contributed positively to profitability in the first half of 2026, although sales recovery and consistent growth across regions have not yet fully materialized. Management remains confident that sales in these key regions will improve in the coming periods and gradually return to growth broadly in line with the structural growth of the O&P industry, supporting a stronger and more resilient Patient Care business over time.

Operations

Gross profit margin of 63% in Q2 2026

Gross profit in 1H 2026 amounted to USD 307 million or 63% of sales, compared to USD 272 million on par with 1H 2025. Gross profit in Q2 2026 amounted to USD 164 million or 63% of sales, compared to USD 144 million or 62% of sales in Q2 2025.

The gross profit margin in Q2 was supported by strong Prosthetics & Neuro Orthotics performance and a USD 4 million U.S. tariff refund (USD 3 million refund net of expenses, as a lower tariff rate remains in effect).

Operating expenses (OPEX)

OPEX ratio of 47% in Q2 2026

OPEX amounted to USD 243 million or 49% of sales in 1H 2026, compared to USD 217 million or 50% of sales in 1H 2025. OPEX amounted to USD 122 million or 47% of sales in Q2 2026, compared to USD 111 million or 48% of sales in Q2 2025.

OPEX growth was 5% organic in the quarter, compared to organic sales growth of 6%, highlighting continued focus on cost control in the quarter.

EBITDA

EBITDA margin before special items of 22% in Q2 2026

EBITDA amounted to USD 98 million or 20% of sales in 1H 2026, compared to EBITDA of USD 85 million or 20% of sales in 1H 2025. EBITDA amounted to USD 58 million or 22% of sales in Q2 2026, compared to USD 49 million in Q2 2025.

The negative effects on EBITDA margin from changes in currencies amounted to roughly 10 basis points net of hedging in Q2 when compared to the same period in 2025.

Financial items

Net financial expenses in 1H 2026 amounted to USD 11 million, compared to USD 17 million in 1H 2025. Net financial expenses in Q2 2026 amounted to USD 5 million, compared to USD 10 million in Q2 2025.

The decrease in net financial expenses was primarily driven by lower net exchange differences compared to the same period last year, resulting in approximately USD 5 million positive impact on net financials in the quarter compared with Q2 2025.

Income tax

Effective tax rate of 23% in Q2 2026

Income tax amounted to USD 13 million in 1H 2026, corresponding to a 23% effective tax rate, compared to USD 10 million in 1H 2025, corresponding to a 24% effective tax rate. Income tax amounted to USD 9 million in Q2 2026, corresponding to a 23% effective tax rate, compared to USD 7 million in Q2 2025, corresponding to a 24% effective tax rate.

Net profit

Net profit margin of 11% in Q2 2026

Net profit grew by 32% in 1H 2026 amounted to USD 44 million or 9% of sales, compared to USD 33 million or 8% of sales in 1H 2025. Net profit grew by 39% in Q2 2026 amounted to USD 29 million or 11% of sales, compared to USD 21 million or 9% of sales in Q2 2025.

Diluted earnings per share in 1H 2026 amounted to 10.2 US cents, compared to 7.8 in 1H 2025. Diluted earnings per share in Q2 2026 amounted to 6.8 US cents, compared to 5.0 in Q2 2025.

Cash flow

Cash generated by operations

Cash generation of USD 52 million in Q2 2026

Cash generated by operations amounted to USD 71 million or 14% of sales in 1H 2026, compared to USD 57 million or 13% of sales in 1H 2025. Cash generated by operations amounted to USD 52 million or 20% of sales in Q2 2026, compared to USD 34 million or 14% of sales in Q2 2025.

Cash generation was solid in the quarter, benefitting from strong operating results, lower net working capital investments than in the comparable quarter and modest CAPEX.

Capital expenditures

CAPEX was 2% of sales in Q2 2026

Capital expenditures in 1H 2026 amounted to USD 11 million or 2% of sales, compared to USD 16 million or 4% of sales in 1H 2025. Capital expenditures in Q2 2026 amounted to USD 6 million or 2% of sales, compared to USD 10 million or 4% of sales in Q2 2025.

The CAPEX ratio for H1 2026 remained slightly below the normalized 3–4% range due to the timing of investments.

Free cash flow

Free cash flow was 12% of sales in Q2 2026

Free cash flow in 1H 2026 amounted to USD 35 million or 7% of sales, compared to USD 20 million or 5% of sales in 1H 2025. Free cash flow in Q2 2026 amounted to USD 31 million or 12% of sales, compared to USD 12 million or 5% of sales in Q2 2025.

Free cash flow was strong for the quarter, benefitting from strong operating results, lower net working capital investments than in the comparable quarter and modest CAPEX.

Bank balances and cash equivalents

Cash and undrawn facilities amounted to USD 166 million

Bank balances and cash equivalents amounted to USD 99 million at the end of Q2 2026 and USD 67 million of existing facilities were undrawn. Bank balances and cash equivalents in addition to undrawn credit facilities at the end of Q2 2026, therefore, amounted to USD 166 million.

Capital structure

Net-interest bearing debt

NIBD/EBITDA before special items at 2.2x

Net interest-bearing debt, including lease liabilities, amounted to USD 435 million at quarter-end Q2 2026 compared to USD 472 million at quarter-end Q2 2025. Net interest-bearing debt to EBITDA before special items corresponded to 2.2x at quarter-end Q2 2026, within the target range of 2.0-3.0x.

Share buybacks and treasury shares

Share buybacks of USD 5.5 million in Q2 2026

The purpose of the program is to reduce the Company's share capital and adjust the capital structure with a desired capital level of 2.0-3.0x net interest-bearing debt to EBITDA before special items, by distributing capital to shareholders in line with the Company's Capital Structure and Capital Allocation Policy.

During Q2 2026, Embla Medical bought back 1,323,653 shares at a market value of approximately USD 5.5 million (1,884,756 shares at a market value of approximately USD 8.1 million 1H 2026). At the end of Q2 2026, treasury shares totaled 2,112,095.

EMBLA MEDICAL®

Financial guidance

Guidance	Guidance FY 2026 (July)	Guidance FY 2026 (April)	Guidance FY 2025 (February)
Sales growth, organic	5-7%	5-8%	5-8%
EBITDA margin before special items	20-22%	20-22%	20-22%
For modelling purposes			
CAPEX as % of sales	3-4%	3-4%	3-4%
Effective tax rate	23-24%	23-24%	23-24%

Guidance for organic sales growth has narrowed and is now expected to be in the range of 5-7% (previously 5-8%).

We continue to expect strong performance in our Prosthetics business across regions in the second half of 2026 supported by solid contributions from our fast-growing bionic portfolio and recently launched innovations. Some positive impact from the US Medicare Coverage Expansion is also expected to contribute to sales supported by our existing portfolio of microprocessor knee (MPK) solutions, which in the future will be complemented by a dedicated K2 MPK solution to better serve the least mobile users in the low active K2 patient population.

In Neuro Orthotics we expect to see the increasing effects from the ongoing roll out of our Neuro Orthotics offerings (Fior & Gentz) into new markets leveraging our global commercial infrastructure and ForMotion footprint within O&P Clinics. Albeit growing from a low base we expect to see solid growth in the EMEA region with some contributions expected in Americas in the second half of 2026 as we roll out our first bionic knee joint “NEURO HiTRONIC MPKAFO”, which received a reimbursement code in 2025 in the important US market.

In Patient Care, we expect growth to gradually improve during 2026 with the aim of eventually returning to consistent sales performance in line with market. Growth in 2026 is expected to be driven by volume growth, increased efficiency supported by effects from the initiatives implemented across our Patient Care business in the second half of 2025. Focus will be on strengthening growth and profitability and benefiting from the structural growth in the O&P industry our product business has observed in recent periods.

Lastly, Bracing & Supports is expected to grow approximately in line with market growth. We assume solid growth in selected key regions supported by launches of new product categories but also with continued competitive pressure in selected markets.

EBITDA margin is expected in the range of 20-22% for 2026 compared to 20% in 2025. The EBITDA margin is expected to be positively impacted by solid sales performance, a favorable product mix from increased sales of our high-end solutions, continued efficiency gains in manufacturing, increasing profitability in Patient Care, and cost control in SG&A.

At current foreign exchange rates, keeping all other factors constant, the EBITDA margin is expected to be neutral net of hedging in 2026 when compared to 2025.

Foreign exchange

Sales are particularly exposed to fluctuations in the EUR/USD exchange rate. Additionally, the ISK has a relatively high impact on operating results as part of manufacturing, R&D and some corporate functions are based in Iceland, while sales in ISK are minimal. A breakdown of sales and costs by main currencies can be found in note 4 of the accompanying Condensed Consolidated Financial Statements.

All else being equal, a +/- 5% movement in EUR/USD is estimated to have an annual impact on EBITDA in the range of +/- USD 3.5-4.5 million when unhedged. The same movement in ISK/USD is estimated to have an annual impact on EBITDA in the range of +/- USD 4.0-5.0 million when unhedged. Embla Medical utilizes forward contracts to hedge approximately 50% of the estimated net currency exposure to ISK.

Currency overview USD	EUR	ISK
Average exchange rate FY 2025	1.130	0.0078
Average exchange rate in Q1 2026	1.170	0.0081
Average exchange rate in Q2 2026	1.163	0.0081
Opening rate July 20 2026	1.144	0.0080
Estimated average exchange rate for FY 2026*	1.155	0.0080
Change in estimated exchange rate FY 2026 compared to last year’s average	2%	3%

*Estimated average exchange rate is calculated as exchange rate (open) on July 20, 2026, for the remainder of the year

Other highlights

Section 232 investigations on MedTech equipment

On 26 September 2025, the US Department of Commerce published a notice for a public consultation on a possible Section 232 Investigation concerning robotics/industrial machinery as well as personal protective equipment (PPE), medical consumables and medical equipment including devices such as hearing aids, prosthetics, orthopedic appliances, ventilators and respirators etc. The objective is to determine the effects on the US national security of imports of these goods. We are currently assessing the scope and potential implications of the Section 232 investigation and the potential trade restrictions that might result from this. As several factors remain uncertain at this stage, we deem it to be too premature to discuss potential impact until more clarity has been revealed.

Completion of the ForMotion rebranding in Patient Care

ForMotion rebranding: All patient care facilities included in the rollout program have now transitioned to the ForMotion brand, marking an important milestone in our patient care transformation uniting our global clinic network under a single, patient-centered brand.

Product launches during the last 12 months

Launch quarter	Segment	Product name	Product description
Q2 2026	**Prosthetics** (Össur)	**New variants of Iceross Dermo Cushion, Iceross Synergy Cushion + Iceross Sleeve**	The dark melange Dermo and Synergy Cushion liners, paired with the black Iceross Sleeve, combine trusted performance with a coordinated design that blends seamlessly with today's black prosthetic components for a cohesive, premium look.
Q2 2026	**Prosthetics** (Streifeneder)	**Kinegen.flow**	New lightweight, waterproof hydraulic prosthetic knee joint delivering a comfortable gait, high stability, a smooth extension stop, and reduced strain.
Q2 2026	**Neuro Orthotics** (Fior & Gentz)	**NEURO HiSWING R+ in 24mm**	The NEURO HiSWING R+ is a microprocessor-controlled, automatic system ankle joint that comes with integrated shock absorption. The new 24mm system width offers greater load-bearing capacity.
Q2 2026	**Neuro Orthotics** (Fior & Gentz)	**NEURO SWING Carbon in 10mm**	The NEURO SWING Carbon is a water-resistant, ultralight system ankle joint made of carbon fiber-reinforced plastics and is now available in 10mm system width.
Q2 2026	**Bracing & Supports** (Össur)	**OA Move**	The new OA Move knee brace brings clinically-proven OA pain relief to those with more active lifestyles. Featuring our 3-Points of Leverage design, dual Dynamic Force System™ straps, and medical-grade compression, OA Move is designed specifically for the needs of more active OA patients.
Q2 2026	**Bracing & Supports** (Össur)	**Formfit® Walker (New Version)**	The Formfit® Walker provides immobilization for patients suffering from soft tissue injury; grades 2 & 3 strains and sprains; and stable fractures. The new lightweight design is 25% lighter than before. Lower heel height reduces leg length discrepancy. The expert-designed orthopedic rocker bottom aids rollover. It has a shock absorbing sole for reduced impact at heel strike.
Q1 2026	**Prosthetics** (Össur)	**AeroFit® Vent**	AeroFit combines a 3D-printed Seal-In liner with a vented socket. The silicone liner increases comfort by reducing humidity accumulation, leaving the limb feeling drier and healthier. The unique design of AeroFit uses the user's own movement to expel air from the socket, promoting airflow leaving the skin feeling drier. Perceived skin health of the residual limb is improved by the micro-hole pattern, meshed silicone structure, and the AeroFit Seal-In liner fabric, which wicks humidity away.
Q4 2025	**Prosthetics** Bionic knee (Össur)	**Power Knee™ Update**	Power Knee™ controls have been updated to deliver functional improvements that enhance mobility and adoption of powered solutions. Synchronous Control™ provides natural, powered motion that adapts seamlessly to each step at any walking speed. Sit-to-stand assistance can now be smoothly ramped and tailored to user preference, while improved stair and stumble-recovery functions deliver more natural transitions and support when it is needed most.

Conference call and

Financial calendar

Conference call details

Embla Medical will host a conference call on July 21, 2026, at **9:00 CET / 7:00 GMT / 3:00 ET**.

To actively participate in the telephone conference, please use the dial-in details provided below:

DK: +45 78 76 84 90

UK: +44 20 3769 6819

US: +1 646 787 0157

Participant access code: 274982

The webcast will be available through following link: Embla Medical Q2 2026 webcast

Financial calendar and events 2026

July 21, 2026	Interim Report Q2 2026
July 21, 2026	Q2 2026 Presentation & Q&A, virtual (HC Andersen Capital)
July 21, 2026	Q2 2026 US Virtual Investor Road Show (Danske Bank)
August 26, 2026	Hamburg Investor Days, Montega, Hamburg
September 2, 2026	Dansk Aktionær Forening Investor Event (Retail), Fredericia
September 10, 2026	Goldman Sachs Medtech Conference, London
September 15, 2026	Berenberg Nordic Seminar, Madrid
September 23, 2026	Bank of America Global Healthcare Conference, London
October 20, 2026	Interim Report Q3 2026
October 20, 2026	Q3 2026 Presentation & Q&A, virtual (HC Andersen Capital)
October 20, 2026	Q3 2026 Investor Road Show, Copenhagen (Danske Bank)
November 10, 2026	Berenberg Nordic Seminar, Paris
November 18-19, 2026	Jefferies Global Healthcare Conference, London
November 24. 2026	Aktie-Info Investor event (retail), Kolding
November 26, 2026	Danske Bank Winter Seminar, Copenhagen
February 2, 2027	Q4 Report 2026 & 2026 Annual Report

For further information

Contact details		
Klaus Sindahl, Head of Investor Relations	+45 5363 0134	ksindahl@emblamedical.com

Embla Medical corporate announcements by e-mail

If you wish to receive Embla Medical's e-mail alerts, please register on our website: https://emblamedical.com/investor-relations

Forward-looking statements

This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Embla Medical undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Embla Medical hf.

Condensed Interim Consolidated Financial Statements

30.6.2026

Embla Medical hf

Grjóthálsi 5

110 Reykjavík

Id-no. 560271-0189

Statement by the Board of Directors and President and CEO

The Condensed Interim Consolidated Financial Statements of Embla Medical hf. for the period from 1 January 2026 to 30 June 2026 consist of the Financial Statements of Embla Medical hf. and its subsidiaries (together referred to as “the Company“ or “Embla Medical“). The Condensed Interim Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standards for Interim Financial Reporting, IAS 34, as adopted by the EU. The Condensed Interim Consolidated Financial Statements have not been audited or reviewed by the Company's auditors.

The total Net sales of the Company amounted to USD 491.0 million and the Net profit amounted to USD 43.8 million. Total assets of the Company amounted to USD 1,717.5 million at the end of period, liabilities were USD 791.4 million and equity was USD 926.0 million.

In our opinion, these Condensed Interim Consolidated Financial Statements present all the information necessary to give a true and fair view of the Company's financial position as at 30 June 2026 and its financial performance and cash flow for the period ended 30 June 2026.

The Board of Directors and the President and CEO of Embla Medical hf. hereby confirm the Condensed Interim Consolidated Financial Statements for the period from 1 January 2026 to 30 June 2026 with their signatures.

Reykjavík, 21 July 2026

Board of Directors

Niels Jacobsen
Chairman of the Board

Svafa Grönfeldt
Vice Chairman of the Board of Directors

Arne Boye Nielsen
Member of the Board of Directors

Alberto Esquenazi
Member of the Board of Directors

Tina Abild Olesen
Member of the Board of Directors

Caroline Vagner Rosenstand
Member of the Board of Directors

President and CEO

Sveinn Sölvason

Consolidated Income Statement

All amounts in USD '000	Notes	1H 2026	1H 2025	Q2 2026	Q2 2025
Net sales	3	490,966	435,203	258,571	232,418
Cost of goods sold		(183,874)	(162,950)	(94,531)	(87,931)
Gross profit		**307,092**	**272,253**	**164,041**	**144,487**
Other income / (expenses)		1,756	814	415	447
Sales and marketing expenses		(177,554)	(160,586)	(90,524)	(82,529)
Research and development expenses		(25,916)	(22,420)	(13,000)	(11,851)
General and administrative expenses		(39,363)	(34,097)	(18,898)	(16,817)
Earnings before interest and tax (EBIT)		**66,014**	**55,964**	**42,033**	**33,737**
Financial income		1,052	1,151	489	476
Financial expenses		(10,392)	(10,318)	(5,528)	(5,069)
Net exchange rate difference		(1,400)	(7,778)	(459)	(5,172)
Net financial expenses		(10,740)	(16,945)	(5,497)	(9,764)
Share in net profit of associates		2,006	4,314	1,785	3,701
Earnings before tax (EBT)		**57,280**	**43,333**	**38,321**	**27,674**
Income tax		(13,455)	(10,192)	(9,002)	(6,561)
Net profit		**43,825**	**33,141**	**29,319**	**21,113**
Attributable to:					
Owners of the Company		43,682	33,069	29,225	20,911
Non-controlling interests		144	72	94	203
Net profit		**43,825**	**33,141**	**29,319**	**21,113**
Earnings per share					
Basic earnings per share (US cent)		10.2	7.8	6.9	5.0
Diluted earnings per share (US cent)		10.2	7.8	6.8	5.0

Consolidated Statement of Comprehensive Income

All amounts in USD '000	1H 2026	1H 2025	Q2 2026	Q2 2025
Net profit	43,825	33,141	29,319	21,113
Items that may be reclassified subsequently to profit or loss:				
Change in cash flow hedges	926	(391)	(176)	(312)
Exchange difference on translating foreign operations	(5,944)	21,478	(2,635)	12,937
Income tax	(1,563)	4,370	(349)	2,948
Other comprehensive income, net of income tax	**(6,581)**	**25,457**	**(3,160)**	**15,573**
Total comprehensive income	**37,245**	**58,598**	**26,160**	**36,686**
Attributable to:				
Owners of the Company	37,101	58,526	26,065	36,483
Non-controlling interests	144	72	94	203
Total comprehensive income	**37,245**	**58,598**	**26,160**	**36,686**

Consolidated Balance Sheet

Assets

All amounts in USD '000	Notes	30.6.2026	31.12.2025
Property, plant and equipment	5	78,311	80,215
Right of use assets	6	155,908	162,514
Goodwill	7	824,987	835,560
Other intangible assets	8	101,689	106,908
Investment in associates		32,119	27,950
Other financial assets		3,855	3,966
Deferred tax assets		53,649	55,380
Non-current assets		**1,250,517**	**1,272,493**
Inventories		161,908	165,617
Accounts receivable		151,900	144,782
Other assets		54,356	45,092
Cash and cash equivalents		98,775	102,507
Current assets		**466,939**	**457,998**
Total assets		**1,717,456**	**1,730,491**

EMBLA MEDICAL™

Consolidated Balance Sheet

Equity and liabilities

All amounts in USD '000	30.6.2026	31.12.2025
Issued capital and share premium	90,322	98,470
Other reserves	(56,699)	(50,494)
Retained earnings	887,008	842,572
Shareholders equity	920,631	890,549
Non-controlling interest	5,397	5,254
Total equity	**926,028**	**895,803**
Borrowings	205,163	292,174
Lease liabilities	146,537	153,499
Deferred tax liabilities	38,253	39,788
Provisions	8,465	8,723
Deferred income	11,265	11,346
Other financial liabilities	8,908	19,588
Non-current liabilities	**418,591**	**525,117**
Borrowings	154,943	67,678
Lease liabilities	27,328	28,218
Accounts payable	39,219	32,825
Income tax payable	19,934	21,322
Provisions	16,093	16,315
Accrued salaries and related expenses	51,983	59,550
Other financial liabilities	22,067	35,673
Other liabilities	41,269	47,989
Current liabilities	**372,836**	**309,571**
Total liabilities	**791,428**	**834,688**
Total equity and liabilities	**1,717,456**	**1,730,491**

Consolidated Statement of Cash Flow

All amounts in USD '000	Notes	1H 2026	1H 2025	Q2 2026	Q2 2025
Earnings before interest and tax (EBIT)		66,014	55,964	42,033	33,737
Depreciation and amortization	5, 6, 8	31,800	29,168	15,952	14,930
Change in inventories		1,674	(6,779)	3,643	1,314
Change in receivables		(18,467)	(23,938)	(17,050)	(20,303)
Change in payables		(8,541)	1,013	6,090	2,691
Change in provisions		(401)	481	729	304
Other operating activities		(900)	809	183	846
Cash generated from operations		**71,179**	**56,718**	**51,580**	**33,519**
Interest received		1,034	1,034	478	380
Interest paid		(10,122)	(9,920)	(5,381)	(4,820)
Income tax paid		(15,758)	(11,826)	(9,598)	(6,880)
Net cash generated from operating activities		**46,333**	**36,006**	**37,079**	**22,199**
Purchase of fixed and intangible assets	5, 8	(11,338)	(16,396)	(5,957)	(10,224)
Acquisition of subsidiaries, net of cash in acquired entities		(281)	0	0	0
Payment of contingent consideration and deferred payments		(21,935)	(4,259)	0	(1,020)
Other investing activities		(1,977)	1,651	(2,129)	3,881
Cash flows used in investing activities		**(35,532)**	**(19,004)**	**(8,086)**	**(7,363)**
Proceeds from long-term borrowings		0	57,732	0	57,756
Repayments of long-term borrowings		0	(57,483)	0	(57,419)
Changes in revolving credit facility		8,780	3,776	(10,714)	(5,017)
Payments of lease liabilities		(15,398)	(13,404)	(8,013)	(6,944)
Purchased treasury shares		(8,148)	(4,281)	(5,532)	(3,004)
Cash flows generated from financing activities		**(14,766)**	**(13,660)**	**(24,259)**	**(14,629)**
Net change in cash		(3,964)	3,343	4,734	207
Exchange rate effects on cash held in foreign currencies		232	4,610	383	2,139
Cash and cash equivalents at beginning of period		102,507	86,163	93,658	91,770
Cash and cash equivalents at end of period		**98,775**	**94,116**	**98,775**	**94,116**

Consolidated Statement of Changes in Equity

All amounts in USD '000	Share capital	Share premium	Other reserves	Retained earnings	Share-holders equity	Non-controlling interests	Total equity
Balance at 1 January 2025	**4,829**	**88,635**	**(75,390)**	**759,112**	**777,186**	**3,513**	**780,699**
Net profit				33,069	**33,069**	72	**33,141**
Change in cash flow hedges			(313)		**(313)**		**(313)**
Transl. diff. of shares in subsidiaries			25,770		**25,770**		**25,770**
Total comprehensive income	0	0	25,457	33,069	**58,526**	72	**58,598**
Share contract charge			902		**902**		**902**
Share contract vested/expired			(2,690)	2,690	**0**		**0**
Purchase of treasury shares	(7)	(4,274)			**(4,281)**		**(4,281)**
Change in non-controlling interests				(219)	**(219)**	219	**0**
Balance at 30 June 2025	**4,822**	**84,361**	**(51,721)**	**794,652**	**832,115**	**3,804**	**835,919**
Balance at 1 January 2026	**4,836**	**93,634**	**(50,494)**	**842,572**	**890,549**	**5,254**	**895,803**
Net profit				43,682	**43,682**	144	**43,825**
Change in cash flow hedges			741		**741**		**741**
Transl. diff. of shares in subsidiaries			(7,322)		**(7,322)**		**(7,322)**
Total comprehensive income	0	0	(6,581)	43,682	**37,101**	144	**37,245**
Share contract charge			1,129		**1,129**		**1,129**
Share contract vested/expired			(754)	754	**0**		**0**
Purchase of treasury shares	(15)	(8,133)			**(8,148)**		**(8,148)**
Balance at 30 June 2026	**4,821**	**85,501**	**(56,699)**	**887,008**	**920,631**	**5,397**	**926,028**

Notes to the Condensed Consolidated Financial Statements

1. Summary of Material Accounting Policies

Statement of compliance

The Condensed Interim Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standard (IFRS) for Interim Financial Reporting, IAS 34, as adopted by the EU. The Condensed Interim Consolidated Financial Statements are presented in accordance with new and amended IFRS accounting standards and interpretations (IFRIC) effective for the period. New and amended IFRS accounting standards, effective for the current year, had minor impact on the Company´s Consolidated Financial Statements. The Company has not early applied new and revised IFRS accounting standards that have been issued but are not yet effective. The Financial Statements are presented in USD, which is the Company's functional currency. They do not include all of the information required for full Annual Consolidated Financial Statements and should be read in conjunction with the Company's Annual Consolidated Financial Statements for the period ended 31 December 2025. The Company's Annual Consolidated Financial Statements can be found on the Company's website www.emblamedical.com.

Basis of preparation

The Condensed Interim Consolidated Financial Statements have been prepared under the historical cost basis except for certain financial instruments that are measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The Condensed Interim Consolidated Financial Statements are presented in USD and all values are rounded to the nearest thousand ('000), except when otherwise indicated. This rounding may impact totals. The accounting policies adopted are consistent with those followed in the preparation of the Company's Annual Consolidated Financial Statements for the period ended 31 December 2025.

2. Quarterly statements

	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025
Net sales	258,571	232,395	256,691	236,795	232,418
Cost of goods sold	(94,531)	(89,343)	(98,625)	(88,559)	(87,931)
Gross profit	164,041	143,052	158,066	148,236	144,487
Gross profit margin	63%	62%	62%	63%	62%
Other income / (expenses)	415	1,341	175	(382)	447
Sales and marketing expenses	(90,524)	(87,031)	(92,194)	(81,400)	(82,529)
Research and development expenses	(13,000)	(12,916)	(11,948)	(11,489)	(11,851)
General and administrative expenses	(18,898)	(20,465)	(21,662)	(18,065)	(16,817)
EBIT	42,033	23,981	32,438	36,900	33,737
Net financial expenses	(5,497)	(5,243)	(2,947)	(4,135)	(9,764)
Share in net profit of associates	1,785	221	1,127	1,220	3,701
EBT	38,321	18,959	30,618	33,984	27,674
Income tax	(9,002)	(4,453)	(5,896)	(8,203)	(6,561)
Net profit	**29,319**	**14,506**	**24,722**	**25,782**	**21,113**
EBITDA	57,985	39,829	47,939	52,850	48,666
EBITDA margin	22%	17%	19%	22%	21%

There were no special items in the above presented quarters.

3. Net Sales

	1H 2026	1H 2025	Q2 2026	Q2 2025
Sales by geographical segment:				
EMEA	257,816	214,625	133,561	113,155
Americas	193,273	186,753	104,613	101,581
APAC	39,876	33,825	20,397	17,681
Total	**490,966**	**435,203**	**258,571**	**232,418**
Sales by business segment:				
Prosthetics & Neuro Orthotics	287,110	237,123	151,399	125,982
Bracing & Supports	76,031	73,088	39,164	38,085
Internal product sales	(21,190)	(18,804)	(11,226)	(9,930)
External product sales	341,952	291,407	179,338	154,137
Patient Care	149,014	143,796	79,233	78,281
Total	**490,966**	**435,203**	**258,571**	**232,418**

4. Sales and expenses split by main currencies

	1H 2026			1H 2025		
	LCY	USD	%	LCY	USD	%
Sales						
USD	170,561	170,561	35%	167,129	167,129	38%
EUR	144,716	168,835	34%	119,627	130,891	30%
ISK	258,489	2,089	0%	263,866	1,979	1%
SEK, NOK, DKK		54,648	11%		52,902	12%
GBP, AUD, CAD & Other		94,834	19%		82,303	19%
Total		**490,966**	**100%**		**435,203**	**100%**
COGS and OPEX						
USD	137,958	137,958	33%	154,153	154,153	41%
EUR	112,432	131,179	31%	80,700	88,259	23%
ISK	5,891,456	47,588	11%	5,849,540	43,871	12%
SEK, NOK, DKK		48,522	11%		49,095	13%
GBP, MXN, CAD & Other		59,705	14%		43,861	12%
Total		**424,952**	**100%**		**379,239**	**100%**

	Q2 2026			Q2 2025		
	LCY	USD	%	LCY	USD	%
Sales						
USD	92,627	92,627	36%	90,667	90,667	39%
EUR	74,463	86,614	33%	60,938	69,150	30%
ISK	150,501	1,218	1%	130,885	1,018	0%
SEK, NOK, DKK		29,150	11%		28,793	12%
GBP, AUD, CAD & Other		48,963	19%		42,790	19%
Total		**258,571**	**100%**		**232,418**	**100%**
COGS and OPEX						
USD	71,638	71,638	33%	79,968	79,968	40%
EUR	56,834	66,108	31%	40,634	46,110	23%
ISK	2,894,025	23,412	11%	2,907,962	22,622	11%
SEK, NOK, DKK		24,713	11%		26,076	13%
GBP, MXN, CAD & Other		30,667	14%		23,905	12%
Total		**216,538**	**100%**		**198,681**	**100%**

The currency split is derived based on the best available information at each reporting date.

5. Property, plant and equipment

2026	Leasehold improvements	Machinery & equipment	Office equipment	Computer equipment	Total
Cost					
At 1 January	62,745	92,228	17,862	15,764	188,600
Additions	1,830	4,357	556	2,190	8,932
Eliminated on disposal	(486)	(213)	(65)	(79)	(843)
Fully depreciated assets	(77)	(174)	(491)	(30)	(771)
Exchange rate differences	(277)	(277)	(261)	(103)	(918)
At 30 June 2026	63,736	95,921	17,602	17,742	195,000
Depreciation					
At 1 January	27,086	58,810	12,175	10,315	108,385
Charge for the period	3,205	4,459	954	1,660	10,278
Eliminated on disposal	(363)	(183)	(42)	(54)	(643)
Fully depreciated assets	(77)	(174)	(491)	(30)	(771)
Exchange rate differences	(159)	(146)	(183)	(73)	(560)
At 30 June 2026	29,693	62,766	12,413	11,818	116,690
At 30 June 2026	**34,043**	**33,155**	**5,188**	**5,924**	**78,311**

Depreciation classified by functional category:	1H 2026	1H 2025	Q2 2026	Q2 2025
Cost of goods sold	4,728	4,965	2,367	2,352
Sales and marketing expenses	2,667	2,001	1,334	1,130
Research and development expenses	703	624	392	361
General and administrative expenses	2,180	1,788	1,084	922
Total	**10,278**	**9,379**	**5,177**	**4,766**

6. Leases

Right of use assets

2026	Buildings & sites	Machinery & equipment	Total
At 1 January	157,857	4,658	162,514
Additions and renewals	8,698	2,728	11,427
Depreciation charge for the period	(13,506)	(1,506)	(15,012)
Eliminated on disposal and termination	(971)	0	(971)
Exchange rate differences	(1,934)	(116)	(2,050)
At 30 June 2026	**150,144**	**5,763**	**155,908**

Depreciation classified by functional category:	1H 2026	1H 2025	Q2 2026	Q2 2025
Cost of goods sold	5,303	5,476	2,648	2,893
Sales and marketing expenses	5,607	4,493	2,796	2,373
Research and development expenses	1,551	1,545	775	816
General and administrative expenses	2,552	2,527	1,274	1,220
Total	**15,012**	**14,041**	**7,493**	**7,302**

7. Goodwill

	30.6.2026	31.12.2025
At 1 January	835,560	776,306
Business combinations	569	18,698
Exchange rate differences	(11,142)	40,556
At end of period	**824,987**	**835,560**

8. Other intangible assets

2026	Customer & distribution relationships	Patents & development costs	Trademarks	Software & other	Total
Cost					
At 1 January	47,559	34,163	8,627	69,448	159,798
Additions	0	71	0	397	468
Additions - internally generated	0	0	0	1,938	1,938
Exchange rate differences	(1,054)	(123)	(201)	(60)	(1,439)
At 30 June 2026	46,505	34,110	8,426	71,724	160,765
Amortization					
At 1 January	13,540	12,379	348	26,623	52,889
Charge for the period	2,101	1,227	140	3,042	6,510
Exchange rate differences	(227)	(50)	(9)	(38)	(324)
At 30 June 2026	15,414	13,555	479	29,627	59,076
At 30 June 2026	**31,091**	**20,555**	**7,947**	**42,096**	**101,689**

Amortization classified by functional category:	1H 2026	1H 2025	Q2 2026	Q2 2025
Cost of goods sold	279	474	117	230
Sales and marketing expenses	3,623	3,492	1,837	1,671
Research and development expenses	959	868	478	472
General and administrative expenses	1,649	914	849	489
Total	**6,510**	**5,749**	**3,282**	**2,862**